GBA1 gene therapy (Spur Therapeutics)

N/A

Report date: 2025/06/11 10:53:35

Base Information

Drug NameGBA1 gene therapy (Spur Therapeutics)
Drug Alias NameGBA1 gene therapy (Freeline Therapeutics)AAV9-GBA1-85
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionBeta-glucocerebrosidase stimulants
TargetsBeta-glucocerebrosidase
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSpur Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesSpur Therapeutics
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A